

=> d ibib abs hitstr 19 1-5

L9 ANSWER 1 OF 5 HCPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:120425 HCPLUS

DOCUMENT NUMBER: 134:305011

TITLE: Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1

AUTHOR(S): Shapiro, Leland; Pott, Gregory B.; Ralston, Annemarie H.

CORPORATE SOURCE: Department of Medicine, Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver, CO, 80262, USA

SOURCE: FASEB Journal (2001), 15(1), 115-122

CODEN: FAJOEC; ISSN: 0892-6638

PUBLISHER: Federation of American Societies for Experimental Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Several observations suggest the existence of potent endogenous suppressors of human immunodeficiency virus type 1 (HIV-1) prodn., and

inhibitors of **serine proteases** may participate in this effect. Alpha-1-antitrypsin (AAT) is the most abundant circulating

serine protease inhibitor. *Physiol. AAT concns.*

inhibited HIV-1 prodn. in chronically infected U1 monocytic cells, reduced virus replication in freshly infected peripheral blood mononuclear cells,

and blocked infection of permissive HeLa cells. In U1 cells, AAT suppressed activation of the HIV-1-inducing transcription factor

NF-*kappa*B. Similar results were obtained using CE-2072, a synthetic inhibitor of host **serine proteases**. HIV-1 did not

replicate in blood obtained from healthy volunteers, but marked replication was obsd. in blood from individuals with hereditary AAT

deficiency. These results identify AAT as a candidate circulating HIV-1 inhibitor *in vivo*. Two different mechanisms of AAT-induced HIV-1

inhibition were identified, including reduced HIV-1 infectivity and blockade of HIV-1 prodn. A novel host-pathogen interaction is suggested,

and an alternative strategy to treat HIV-1-related disease may be possible.

IT 9041-92-3 208840-22-6, CE-2072

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use);

BIOL (Biological study); PROC (Process); USES (Uses)

(alpha-1-antitrypsin inhibits HIV-1)

RN 9041-92-3 HCPLUS


CN Trypsin inhibitor, .alpha.1- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 208840-22-6 HCPLUS

CN L-Proline, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2000:628160 HCAPLUS
 DOCUMENT NUMBER: 133:232870
 TITLE: Inhibitors of **serine protease** activity, and methods and compositions for treatment of viral infections and other conditions
 INVENTOR(S): **Shapiro, Leland**
 PATENT ASSIGNEE(S): The Trustees of University Technology Corp., USA
 SOURCE: PCT Int. Appl., 87 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000052034	A2	20000908	WO 2000-US5558	20000303
WO 2000052034	A3	20010111		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 1999-123167P P 19990305
 US 1999-137795P P 19990603

OTHER SOURCE(S): MARPAT 133:232870
 AB A method of treating and preventing viral infection is provided. In particular, a method of blocking viral infection facilitated by a serine proteolytic activity is disclosed, which consists of administering to a subject suffering or about to suffer from viral infection a therapeutically effective amt. of a compd. having a **serine protease** inhibitory or serpin activity. Among compds. are .alpha.1-antitrypsin (AAT), peptide derivs. from the carboxyterminal end of AAT, and man-made, synthetic compds. mimicking the action of such compds. The preferred viral infections include retroviral infection such

as human immunodeficiency virus (HIV) infection. A method for treating other pathol. conditions mediated my a **serine protease** is also disclosed.

IT 9068-38-6, Reverse transcriptase 144114-21-6,
Retropepsin

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HIV, inhibitors; **serine protease** inhibitors for
treatment of viral infections and other conditions, and use with other
agents)

RN 9068-38-6 HCPLUS

CN Nucleotidyltransferase, deoxyribonucleate, RNA-dependent (9CI) (CA INDEX
NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 144114-21-6 HCPLUS

CN Retropepsin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 9001-90-5, Plasmin 9002-04-4, Thrombin 9004-06-2

, Elastase 9004-07-3, Chymotrypsin 56645-49-9,
Cathepsin G 64886-91-5, Eglin 105913-11-9, Plasminogen
activator 128028-50-2, Proteinase-3

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; **serine protease** inhibitors for
treatment of viral infections and other conditions, and use with other
agents)

RN 9001-90-5 HCPLUS

CN Plasmin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9002-04-4 HCPLUS

CN Thrombin (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9004-06-2 HCPLUS

CN Elastase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9004-07-3 HCPLUS

CN Chymotrypsin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 56645-49-9 HCPLUS

CN Cathepsin G (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 64886-91-5 HCPLUS

CN Proteinase inhibitor, eglin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 105913-11-9 HCPLUS

CN Plasminogen activator (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 128028-50-2 HCPLUS

CN Myeloblastin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 9041-92-3, .alpha.1-Antitrypsin
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (serine protease inhibitors for treatment of viral infections and other conditions, and use with other agents)

RN 9041-92-3 HCAPLUS

CN Trypsin inhibitor, .alpha.1- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 145852-04-6 145852-05-7 145852-06-8
 145852-07-9 145852-08-0 145852-14-8
 145852-15-9 180526-15-2 291296-75-8
 291296-76-9 291296-77-0 291296-78-1
 291296-79-2 291296-80-5 291296-81-6
 291296-82-7 291296-83-8 291296-84-9


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(serine protease inhibitors for treatment of viral infections and other conditions, and use with other agents)

RN 145852-04-6 HCAPLUS

CN L-Methionine, L-phenylalanyl-L-valyl-L-phenylalanyl-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145852-05-7 HCAPLUS

CN L-Isoleucine, L-phenylalanyl-L-valyl-L-tyrosyl-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145852-06-8 HCAPLUS

CN L-Methionine, L-alanyl-L-valyl-L-phenylalanyl-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145852-07-9 HCAPLUS

CN L-Alanine, L-phenylalanyl-L-valyl-L-phenylalanyl-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145852-08-0 HCAPLUS

CN L-Methionine, L-phenylalanyl-L-valyl-L-alanyl-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145852-14-8 HCAPLUS

CN L-Methionine, L-phenylalanyl-L-alanyl-L-phenylalanyl-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145852-15-9 HCAPLUS

CN L-Methionine, L-phenylalanyl-L-valyl-L-phenylalanyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 180526-15-2 HCPLUS

CN L-Isoleucine, L-phenylalanyl-L-leucyl-L-phenylalanyl-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 291296-75-8 HCPLUS

CN L-Isoleucine, L-phenylalanyl-L-leucyl-L-valyl-L-phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 291296-76-9 HCPLUS

CN L-Isoleucine, L-phenylalanyl-L-leucyl-L-methionyl-L-isoleucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 291296-77-0 HCAPLUS

CN L-Leucine, L-phenylalanyl-L-leucyl-L-phenylalanyl-L-valyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 291296-78-1 HCAPLUS

CN L-Valine, L-phenylalanyl-L-leucyl-L-phenylalanyl-L-valyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 291296-79-2 HCAPLUS

CN L-Isoleucine, L-phenylalanyl-L-leucyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 291296-80-5 HCPLUS

CN L-Isoleucine, L-phenylalanyl-L-leucyl-L-methionyl-L-phenylalanyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 291296-81-6 HCPLUS

CN L-Isoleucine, L-phenylalanyl-L-methionyl-L-leucyl-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 291296-82-7 HCPLUS

CN L-Isoleucine, L-phenylalanyl-L-isoleucyl-L-isoleucyl-L-methionyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 291296-83-8 HCPLUS

CN L-Isoleucine, L-phenylalanyl-L-leucyl-L-phenylalanyl-L-cysteinyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 291296-84-9 HCAPLUS

CN L-Valine, L-phenylalanyl-L-leucyl-L-phenylalanyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 127-07-1, Hydrea 147-85-3D, L-Proline, analogs,
 biological studies 289-06-5D, Thiadiazole, derivs.
 3056-17-5, Zerit 7481-89-2, Hivid 11120-54-0D,
 Oxadiazole, derivs. 30516-87-1, Retrovir 37306-44-8D,
 Triazole, derivs. 69655-05-6, Videx 127779-20-8,
 Fortovase 129618-40-2, Viramune 134678-17-4, Epivir
 136470-78-5, Ziagen 142340-99-6, Preveon
 147221-93-0, Rescriptor 147318-81-8, KNI-272
 154598-52-4, Sustiva 155213-67-5, Norvir
 157810-81-6, Crixivan 159989-65-8, Viracept
 161814-49-9, Angenerase 165456-81-5, Combivir
 166335-18-8, U-103017 175385-62-3, CGP-61755
 179752-50-2 179752-51-3 179752-52-4
 179752-53-5 179752-54-6 179752-55-7
 179752-56-8 179752-57-9 179752-58-0
 179752-59-1 179752-60-4 179752-61-5
 179752-62-6 179752-64-8 179752-65-9
 208840-11-3 208840-12-4 208840-13-5
 208840-14-6 208840-18-0 208840-19-1
 208840-20-4 208840-21-5 208840-22-6
 208840-24-8 208840-25-9 208840-27-1
 208840-28-2 208840-39-5 208845-34-5
 208845-35-6 208845-38-9 208845-39-0
 208845-40-3 208845-43-6 208845-56-1
 208845-62-9 208845-63-0 208845-65-2
 208845-66-3 208845-77-6 208845-85-6
 208846-02-0 208846-03-1 208846-13-3

208847-42-1 208847-55-6 291518-83-7


291518-83-7D, derivs.

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(serine protease inhibitors for treatment of viral infections and other conditions, and use with other agents)

RN 127-07-1 HCPLUS


CN Urea, hydroxy- (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 147-85-3 HCPLUS


CN L-Proline (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 289-06-5 HCPLUS


CN 1,3,4-Thiadiazole (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 3056-17-5 HCPLUS

CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 7481-89-2 HCPLUS

CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 11120-54-0 HCAPLUS
 CN Oxadiazole (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 30516-87-1 HCAPLUS
 CN Thymidine, 3'-azido-3'-deoxy- (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 37306-44-8 HCAPLUS
 CN Triazole (6CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 69655-05-6 HCAPLUS
 CN Inosine, 2',3'-dideoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 127779-20-8 HCAPLUS
 CN Butanediamide, N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129618-40-2 HCAPLUS


CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 134678-17-4 HCAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 136470-78-5 HCAPLUS


CN 2-Cyclopentene-1-methanol, 4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-, (1S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 142340-99-6 HCAPLUS

CN Propanoic acid, 2,2-dimethyl-, [[[2-(6-amino-9H-purin-9-yl)ethoxy]methyl]phosphinylidene]bis(oxymethylene) ester (9CI) (CA INDEX NAME)




RN 147221-93-0 HCAPLUS

CN Piperazine, 1-[3-[(1-methylethyl)amino]-2-pyridinyl]-4-[(5-[(methylsulfonyl)amino]-1H-indol-2-yl]carbonyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 136817-59-9

CMF C22 H28 N6 O3 S




CM 2

CRN 75-75-2
 CMF C H4 O3 S




RN 147318-81-8 HCAPLUS
 CN 4-Thiazolidinecarboxamide, N-(1,1-dimethylethyl)-3-[(2S,3S)-2-hydroxy-3-[(2R)-2-[(5-isoquinolinyloxy)acetyl]amino]-3-(methylthio)-1-oxopropyl]amino]-1-oxo-4-phenylbutyl]-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 154598-52-4 HCAPLUS
 CN 2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 155213-67-5 HCAPLUS
 CN 2,4,7,12-Tetraazatridecan-13-oic acid, 10-hydroxy-2-methyl-5-(1-methylethyl)-1-[2-(1-methylethyl)-4-thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-, 5-thiazolylmethyl ester, (5S,8S,10S,11S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157810-81-6 HCAPLUS


CN D-erythro-Pentonamide, 2,3,5-trideoxy-N-[(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-5-[(2S)-2-[(1,1-dimethylethyl)amino]carbonyl]-4-(3-pyridinylmethyl)-1-piperazinyl]-2-(phenylmethyl)-, sulfate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 150378-17-9

CMF C36 H47 N5 O4


Absolute stereochemistry.



CM 2

CRN 7664-93-9

CMF H2 O4 S




RN 159989-65-8 HCAPLUS

CN 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3S,4aS,8aS)-, monomethanesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 159989-64-7
 CMF C32 H45 N3 O4 S

Absolute stereochemistry.




CM 2

CRN 75-75-2
 CMF C H4 O3 S



RN 161814-49-9 HCPLUS
 CN Carbamic acid, [(1S,2R)-3-[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl-, (3S)-tetrahydro-3-furanyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 165456-81-5 HCPLUS
 CN Thymidine, 3'-azido-3'-deoxy-, mixt. with 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone (9CI) (CA INDEX NAME)

CM 1

CRN 134678-17-4
CMF C8 H11 N3 O3 S


Absolute stereochemistry. Rotation (-).




CM 2

CRN 30516-87-1
CMF C10 H13 N5 O4

Absolute stereochemistry. Rotation (+).




RN 166335-18-8 HCAPLUS
CN Benzenesulfonamide, 4-cyano-N-[3-[cyclopropyl(5,6,7,8,9,10-hexahydro-4-hydroxy-2-oxo-2H-cycloocta[b]pyran-3-yl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 175385-62-3 HCAPLUS
CN 2-Oxa-5,8,14-triazapentadecan-15-oic acid, 12-hydroxy-7-(1-methylethyl)-6,9-dioxo-13-(phenylmethyl)-10-[(2,3,4-trimethoxyphenyl)methyl]-, (7S,10R,12S,13S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-50-2 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[[5-[[3-(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-51-3 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[[5-(2-phenylethyl)-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-52-4 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[[5-[(2-methoxyphenyl)methyl]-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-53-5 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-54-6 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-methyl-1,2,4-oxadiazol-3-yl)carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-55-7 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[(5-difluoromethyl)-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-56-8 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy) carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-(phenylmethyl)-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-57-9 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[[5-[(3-methoxyphenyl)methyl]-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-58-0 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[[5-[(2,6-difluorophenyl)methyl]-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]-(S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-59-1 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[[5-[(1E)-2-phenylethenyl]-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 179752-60-4 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[[5-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 179752-61-5 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[[5-[(1E)-2-(4-methoxyphenyl)ethenyl]-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 179752-62-6 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-(3-thienylmethyl)-1,2,4-oxadiazol-3-yl)carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-64-8 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-phenyl-1,2,4-oxadiazol-3-yl)carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-65-9 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-(3-phenylpropyl)-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-11-3 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[(5-[(3,5-dimethylphenyl)methyl]-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-12-4 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[(5-[(3,5-dimethoxyphenyl)methyl]-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-13-5 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[[5-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-14-6 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[[5-[(3-methylphenyl)methyl]-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-18-0 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[[5-([1,1'-biphenyl]-4-ylmethyl)-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-19-1 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[[5-([1,1'-biphenyl]-3-ylmethyl)-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-20-4 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[[5-[(3-phenoxyphenyl)methyl]-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-21-5 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[(5-(cyclohexylmethyl)-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]- (9CI). (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-22-6 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-24-8 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-25-9 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-[[3-(trifluoromethyl)phenyl]methyl]-1,3,4-oxadiazol-2-yl)carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-27-1 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-(1-naphthalenylmethyl)-1,2,4-oxadiazol-3-yl)carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-28-2 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-[(3-pyridinylmethyl)-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-39-5 HCPLUS

CN 1(6H)-Pyrimidineacetamide, 5-amino-2-(4-fluorophenyl)-N-[(1S)-2-methyl-1-[(5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]-6-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 208845-34-5 HCAPLUS

CN Carbamic acid, [2-(4-fluorophenyl)-1,6-dihydro-1-[2-[(1*S*)-2-methyl-1-[[5-[[3-(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-3-yl]carbonyl]propyl]amino]-2-oxoethyl]-6-oxo-5-pyrimidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-35-6 HCAPLUS

CN 1(6H)-Pyrimidineacetamide, 5-amino-2-(4-fluorophenyl)-N-[(1*S*)-2-methyl-1-[[5-[[3-(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-3-yl]carbonyl]propyl]-6-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-38-9 HCPLUS

CN Carbamic acid, [2-(4-fluorophenyl)-1,6-dihydro-1-[2-[(1*S*)-2-methyl-1-[(5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl)carbonyl]propyl]amino]-2-oxoethyl]-6-oxo-5-pyrimidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-39-0 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1*S*)-2-methyl-1-[(5-[(1,1':3',1''-terphenyl)-5'-ylmethyl]-1,3,4-oxadiazol-2-yl)carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-40-3 HCAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[2-[[[1S)-2-methyl-1-[[5-[[3-(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-3-yl]carbonyl]propyl]amino]-2-oxoethyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-43-6 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[[5-[[4-(dimethylamino)phenyl]methyl]-1,2,4-oxadiazol-2-yl]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-56-1 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[[5-[[4-(dimethylamino)phenyl]methyl]-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-62-9 HCAPLUS

CN 3-Thiazolidineacetamide, N-[(1S)-2-methyl-1-[[5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]-4-oxo-2-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-63-0 HCAPLUS

CN 3-Thiazolidineacetamide, N-[(1S)-2-methyl-1-[[5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]-4-oxo-2-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-65-2 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(1-naphthalenylmethyl)-1,3,4-oxadiazol-2-yl]carbonyl]propyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-66-3 HCAPLUS

CN Carbamic acid, [(1S)-1-[(2S)-2,3-dihydro-2-[[[(1S)-2-methyl-1-[[5-[[3-(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-3-yl]carbonyl]propyl]amino]carbonyl]-1H-indol-1-yl]carbonyl]-2-methylpropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-77-6 HCAPLUS

CN 3-Thiazolidineacetamide, N-[(1S)-2-methyl-1-[[5-[[3-(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-3-yl]carbonyl]propyl]-4-oxo-2-(phenylmethyl)-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 208845-85-6 HCAPLUS

CN Carbamic acid, [(1S)-1-[(2S)-2,3-dihydro-2-[[[(1S)-2-methyl-1-[[5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]amino]carbonyl]-

1H-indol-1-yl]carbonyl]-2-methylpropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208846-02-0 HCPLUS

CN 1H-Pyrrole-2-carboxamide, N-[2-[[(1S)-2-methyl-1-[[5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]amino]-2-oxoethyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208846-03-1 HCPLUS

CN 1H-Indole-2-carboxamide, 1-acetyl-2,3-dihydro-N-[(1S)-2-methyl-1-[[5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208846-13-3 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[[5-(1,3-benzodioxol-5-ylmethyl)-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208847-42-1 HCAPLUS

CN Carbamic acid, [(2S,5S)-1,2,4,5,6,7-hexahydro-2-[[[(1S)-2-methyl-1-[[5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]amino]carbonyl]-4-oxoazepino[3,2,1-hi]indol-5-yl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208847-55-6 HCAPLUS

CN 3-Thiazolidineacetamide, N-[(1S)-1-[hydroxy[5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]methyl]-2-methylpropyl]-4-oxo-2-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 291518-83-7 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-[(4-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 291518-83-7 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-[(4-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 37259-58-8, Serine protease

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(serine protease inhibitors for treatment of viral infections and other conditions, and use with other agents)

RN 37259-58-8 HCAPLUS
 CN Proteinase, serine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L9 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2000:628010 HCAPLUS
 DOCUMENT NUMBER: 133:217681
 TITLE: Inhibitors of **serine protease**
 activity, and methods and compositions for treatment
 of herpes virus infections
 INVENTOR(S): **Shapiro, Leland**
 PATENT ASSIGNEE(S): The Trustees of University Technology Corporation, USA
 SOURCE: PCT Int. Appl., 89 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000051625	A1	20000908	WO 2000-US5557	20000303
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 1999-123167P	P 19990305
			US 1999-153942P	P 19990915

OTHER SOURCE(S): MARPAT 133:217681
 AB Compns. and methods of treating and preventing a viral infection are provided. A method of blocking a viral infection facilitated by a serine proteolytic (SP) activity is disclosed, which involves administering to a subject suffering or about to suffer from a viral infection a therapeutically effective amt. of a substance having **serine protease** inhibitory activity or serpin activity. Among the substances found to be useful are .alpha.1-antitrypsin (AAT), peptide derivs. from the carboxy terminal end of AAT and synthetic drugs mimicking the action of such substances. The invention is particularly well suited for checking a viral infection mediated by members of herpesviridae family.

IT 37259-58-8, Serine protease
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (serine protease inhibitors and methods and compns.
 for treatment of herpes virus infections)

RN 37259-58-8 HCAPLUS
 CN Proteinase, serine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 9041-92-3, .alpha.1 Antitrypsin
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological

process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (serine protease inhibitors and methods and compns.
 for treatment of herpes virus infections)


RN 9041-92-3 HCAPLUS
 CN Trypsin inhibitor, .alpha.1- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 145852-04-6 145852-05-7 145852-06-8
 145852-07-9 145852-08-0 145852-14-8
 145852-15-9 180526-15-2 291296-75-8
 291296-76-9 291296-77-0 291296-78-1
 291296-79-2 291296-80-5 291296-81-6
 291296-82-7 291296-83-8 291296-84-9
 291296-85-0 291296-86-1 291296-87-2
 291296-88-3 291296-89-4 291296-90-7
 291296-91-8 291296-92-9 291296-93-0
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (serine protease inhibitors and methods and compns.
 for treatment of herpes virus infections)


RN 145852-04-6 HCAPLUS
 CN L-Methionine, L-phenylalanyl-L-valyl-L-phenylalanyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 145852-05-7 HCAPLUS
 CN L-Isoleucine, L-phenylalanyl-L-valyl-L-tyrosyl-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145852-06-8 HCAPLUS

CN L-Methionine, L-alanyl-L-valyl-L-phenylalanyl-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145852-07-9 HCAPLUS

CN L-Alanine, L-phenylalanyl-L-valyl-L-phenylalanyl-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145852-08-0 HCAPLUS

CN L-Methionine, L-phenylalanyl-L-valyl-L-alanyl-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145852-14-8 HCAPLUS

CN L-Methionine, L-phenylalanyl-L-alanyl-L-phenylalanyl-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145852-15-9 HCAPLUS

CN L-Methionine, L-phenylalanyl-L-valyl-L-phenylalanyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 180526-15-2 HCAPLUS

CN L-Isoleucine, L-phenylalanyl-L-leucyl-L-phenylalanyl-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 291296-75-8 HCAPLUS

CN L-Isoleucine, L-phenylalanyl-L-leucyl-L-valyl-L-phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 291296-76-9 HCAPLUS

CN L-Isoleucine, L-phenylalanyl-L-leucyl-L-methionyl-L-isoleucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 291296-77-0 HCAPLUS

CN L-Leucine, L-phenylalanyl-L-leucyl-L-phenylalanyl-L-valyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 291296-78-1 HCAPLUS

CN L-Valine, L-phenylalanyl-L-leucyl-L-phenylalanyl-L-valyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 291296-79-2 HCAPLUS

CN L-Isoleucine, L-phenylalanyl-L-leucyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 291296-80-5 HCPLUS

CN L-Isoleucine, L-phenylalanyl-L-leucyl-L-methionyl-L-phenylalanyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 291296-81-6 HCPLUS

CN L-Isoleucine, L-phenylalanyl-L-methionyl-L-leucyl-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 291296-82-7 HCAPLUS

CN L-Isoleucine, L-phenylalanyl-L-isoleucyl-L-isoleucyl-L-methionyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 291296-83-8 HCAPLUS

CN L-Isoleucine, L-phenylalanyl-L-leucyl-L-phenylalanyl-L-cysteinyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 291296-84-9 HCPLUS

CN L-Valine, L-phenylalanyl-L-leucyl-L-phenylalanyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 291296-85-0 HCPLUS

CN L-Valine, L-phenylalanyl-L-cysteinyl-L-isoleucyl-L-cysteinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 291296-86-1 HCPLUS

CN L-Phenylalanine, L-phenylalanyl-L-cysteinyl-L-valyl-L-cysteinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 291296-87-2 HCPLUS

CN L-Valine, L-phenylalanyl-L-isoleucyl-L-valyl-L-cysteinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 291296-88-3 HCPLUS

CN L-Valine, L-phenylalanyl-L-cysteinyl-L-valylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 291296-89-4 HCPLUS

CN L-Valine, L-phenylalanyl-L-cysteinyl-L-valyl-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 291296-90-7 HCAPLUS

CN L-Valine, L-phenylalanyl-L-leucyl-L-valylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 291296-91-8 HCAPLUS

CN L-Valine, L-phenylalanyl-L-seryl-L-valyl-L-seryl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 291296-92-9 HCAPLUS

CN L-Valine, L-phenylalanyl-L-seryl-L-valyl-L-cysteinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 291296-93-0 HCAPLUS

CN Glycine, L-phenylalanyl-L-valyl-L-cysteinyl-L-valyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 98-10-2D, Benzenesulfonamide, derivs. 289-06-5D,
 Thiadiazole, derivs. 11120-54-0D, Oxadiazole, derivs.
 27988-97-2D, Tetrazole, derivs. 37306-44-8D, Triazole,
 peptoid derivs. 179752-50-2 179752-51-3
 179752-52-4 179752-53-5 179752-54-6
 179752-55-7 179752-56-8 179752-57-9
 179752-58-0 179752-59-1 179752-60-4
 179752-61-5 179752-62-6 179752-64-8
 179752-65-9 208840-11-3 208840-12-4
 208840-13-5 208840-14-6 208840-18-0
 208840-19-1 208840-20-4 208840-21-5
 208840-22-6 208840-24-8 208840-25-9
 208840-27-1 208840-28-2 208840-39-5
 208845-34-5 208845-35-6 208845-38-9
 208845-39-0 208845-40-3 208845-43-6
 208845-56-1 208845-62-9 208845-63-0
 208845-65-2 208845-66-3 208845-77-6
 208845-85-6 208846-02-0 208846-03-1
 208846-13-3 208847-42-1 208847-55-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(serine protease inhibitors and methods and compns.
 for treatment of herpes virus infections)

RN 98-10-2 HCAPLUS

CN Benzenesulfonamide (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 289-06-5 HCAPLUS
 CN 1,3,4-Thiadiazole (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 11120-54-0 HCAPLUS
 CN Oxadiazole (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 RN 27988-97-2 HCAPLUS
 CN Tetrazole (6CI, 7CI, 9CI) (CA INDEX NAME)

CM 1


CRN 6054-75-7
 CMF C H6 N4



RN 37306-44-8 HCAPLUS
 CN Triazole (6CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 RN 179752-50-2 HCAPLUS
 CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[[5-[[3-(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-51-3 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-(2-phenylethyl)-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-52-4 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[(5-[(2-methoxyphenyl)methyl]-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-53-5 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-54-6 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-methyl-1,2,4-oxadiazol-3-yl)carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-55-7 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[(5-(difluoromethyl)-1,2,4-oxadiazol-3-yl)carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-56-8 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[[5-(phenylmethyl)-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-57-9 HCAPLUS.

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[[5-[(3-methoxyphenyl)methyl]-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-58-0 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[[5-[(2,6-difluorophenyl)methyl]-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 179752-59-1 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[[5-[(1E)-2-phenylethenyl]-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 179752-60-4 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[[5-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 179752-61-5 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[(5-[(1E)-2-(4-methoxyphenyl)ethenyl]-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 179752-62-6 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-(3-thienylmethyl)-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-64-8 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-phenyl-1,2,4-oxadiazol-3-yl)carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-65-9 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-(3-phenylpropyl)-1,2,4-oxadiazol-3-yl)carbonyl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 208840-11-3 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[(5-[(3,5-

dimethylphenyl)methyl]-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-12-4 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[[5-[(3,5-dimethoxyphenyl)methyl]-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-13-5 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[[5-[(3,5-bis(trifluoromethyl)phenyl)methyl]-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-14-6 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-[(3-methylphenyl)methyl]-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-18-0 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[(5-[(1,1'-biphenyl)-4-ylmethyl]-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-19-1 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[[5-((1,1'-biphenyl)-3-yl)methyl]-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-20-4 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[[5-((3-phenoxyphenyl)methyl)-1,2,4-oxadiazol-3-yl]carbonyl]propyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-21-5 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[[5-(cyclohexylmethyl)-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-22-6 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl)carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-24-8 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl)carbonyl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 208840-25-9 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-

[(3-(trifluoromethyl)phenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-27-1 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-(1-naphthalenylmethyl)-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-28-2 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[[5-(3-pyridinylmethyl)-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-39-5 HCPLUS

CN 1(6H)-Pyrimidineacetamide, 5-amino-2-(4-fluorophenyl)-N-[(1S)-2-methyl-1-[5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]-6-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 208845-34-5 HCPLUS

CN Carbamic acid, [2-(4-fluorophenyl)-1,6-dihydro-1-[2-[(1S)-2-methyl-1-[5-[(3-(trifluoromethyl)phenyl)methyl]-1,2,4-oxadiazol-3-yl]carbonyl]propyl]amino]-2-oxoethyl]-6-oxo-5-pyrimidinyl-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-35-6 HCAPLUS

CN 1(6H)-Pyrimidineacetamide, 5-amino-2-(4-fluorophenyl)-N-[(1S)-2-methyl-1-[[5-[[3-(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-3-yl]carbonyl]propyl]-6-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-38-9 HCAPLUS

CN Carbamic acid, [2-(4-fluorophenyl)-1,6-dihydro-1-[[2-[(1S)-2-methyl-1-[[5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]amino]-2-oxoethyl]-6-oxo-5-pyrimidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-39-0 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[[5-([1,1':3',1''-terphenyl]-5'-ylmethyl)-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-40-3 HCAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[2-[[[(1S)-2-methyl-1-[[5-[(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-3-yl]carbonyl]propyl]amino]-2-oxoethyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-43-6 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[[5-[(4-(dimethylamino)phenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-56-1 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[(5-[(4-dimethylaminophenyl)methyl]-1,3,4-oxadiazol-2-yl)carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-62-9 HCAPLUS

CN 3-Thiazolidineacetamide, N-[(1S)-2-methyl-1-[(5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl)carbonyl]propyl]-4-oxo-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 208845-63-0 HCAPLUS

CN 3-Thiazolidineacetamide, N-[(1S)-2-methyl-1-[(5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl)carbonyl]propyl]-4-oxo-2-(phenylmethyl)- (9CI) (CA INDEX NAME)

(INDEX NAME)


Absolute stereochemistry.



RN 208845-65-2 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy) carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[[5-(1-naphthalenylmethyl)-1,3,4-oxadiazol-2-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-66-3 HCPLUS

CN Carbamic acid, [(1S)-1-[(2S)-2,3-dihydro-2-[[[(1S)-2-methyl-1-[[5-[(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-3-yl]carbonyl]propyl]amino]carbonyl]-1H-indol-1-yl]carbonyl]-2-methylpropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-77-6 HCAPLUS

CN 3-Thiazolidineacetamide, N-[(1S)-2-methyl-1-[[5-[[3-(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-3-yl]carbonyl]propyl]-4-oxo-2-(phenylmethyl)-, 1-oxide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-85-6 HCAPLUS

CN Carbamic acid, [(1S)-1-[(2S)-2,3-dihydro-2-[[[(1S)-2-methyl-1-[[5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]amino]carbonyl]-1H-indol-1-yl]carbonyl]-2-methylpropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208846-02-0 HCAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[2-[[[(1S)-2-methyl-1-[[5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]amino]-2-oxoethyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 208846-03-1 HCAPLUS

CN 1H-Indole-2-carboxamide, 1-acetyl-2,3-dihydro-N-[(1S)-2-methyl-1-[[5-[(3-

methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]-, (2S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 208846-13-3 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[(5-(1,3-benzodioxol-5-ylmethyl)-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208847-42-1 HCAPLUS

CN Carbamic acid, [(2S,5S)-1,2,4,5,6,7-hexahydro-2-[(1S)-2-methyl-1-[(5-(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]amino]carbonyl]-4-oxoazepino[3,2,1-hi]indol-5-yl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208847-55-6 HCAPLUS

CN 3-Thiazolidineacetamide, N-[(1S)-1-[hydroxy[5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]methyl]-2-methylpropyl]-4-oxo-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 9004-06-2, Elastase 56645-49-9, Cathepsin G

128028-50-2, Proteinase-3 186322-81-6, Caspase

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(serine protease inhibitors and methods and compns.
for treatment of herpes virus infections)

RN 9004-06-2 HCAPLUS

CN Elastase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 56645-49-9 HCAPLUS

CN Cathepsin G (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 128028-50-2 HCAPLUS

CN Myeloblastin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 186322-81-6 HCAPLUS

CN Caspase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 292094-96-3

RL: PRP (Properties)

(unclaimed protein sequence; inhibitors of **serine protease** activity, and methods and compns. for treatment of herpes virus infections)

RN 292094-96-3 HCAPLUS

CN 1: PN: WO0051625 PAGE: 2 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:628009 HCAPLUS

DOCUMENT NUMBER: 133:217725

TITLE: Methods and compositions using **serine protease** inhibitors useful in inhibiting apoptosis, and therapeutic use thereofINVENTOR(S): **Shapiro, Leland**

PATENT ASSIGNEE(S): The Trustees of University Technology Corporation, USA

SOURCE: PCT Int. Appl., 30 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000051624	A2	20000908	WO 2000-US6069	20000303
WO 2000051624	A3	20001228		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 1999-123167P P 19990305

AB A method is provided for treating an animal suffering a disease characterized by excessive apoptosis by administering a therapeutically effective amt. of at least one **serine protease** inhibitor and thereafter monitoring a decrease in apoptosis. The inhibitor of the invention includes .alpha.1-antitrypsin or an .alpha.1-antitrypsin-like agent, including but not limited to oxidn.-resistant variants of .alpha.1-antitrypsin, and peptoids with antitrypsin activity. The diseases treatable by the invention include cancer, autoimmune disease, sepsis neurodegenerative disease, myocardial infarction, stroke, ischemia-reperfusion injury, toxin induced liver injury and AIDS. The method of the invention is also suitable for the prevention or amelioration of diseases characterized by excessive apoptosis.

IT 9004-06-2, Elastase 56645-49-9, Cathepsin G

128028-50-2, Proteinase-3

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors; **serine protease** inhibitors for
 inhibiting apoptosis, and therapeutic use)

RN 9004-06-2 HCPLUS

CN Elastase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 56645-49-9 HCPLUS

CN Cathepsin G (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 128028-50-2 HCPLUS

CN Myeloblastin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


IT 289-06-5D, Thiadiazole, derivs. 9041-92-3, .alpha.1
 Antitrypsin 9041-92-3D, .alpha.1 Antitrypsin, variants
 11120-54-0D, Oxadiazole, derivs. 37306-44-8D, Triazole,
 derivs. 179752-50-2 179752-51-3 179752-52-4
 179752-53-5 179752-54-6 179752-55-7
 179752-56-8 179752-57-9 179752-58-0
 179752-59-1 179752-60-4 179752-61-5
 179752-62-6 179752-64-8 179752-65-9
 208840-11-3 208840-12-4 208840-13-5
 208840-14-6 208840-18-0 208840-19-1
 208840-20-4 208840-21-5 208840-22-6
 208840-24-8 208840-25-9 208840-27-1
 208840-28-2 208840-39-5 208845-34-5
 208845-35-6 208845-38-9 208845-39-0
 208845-40-3 208845-43-6 208845-56-1
 208845-62-9 208845-63-0 208845-65-2
 208845-66-3 208845-77-6 208845-85-6
 208846-02-0 208846-03-1 208846-13-3
 208847-42-1 208847-55-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**serine protease** inhibitors for inhibiting
 apoptosis, and therapeutic use)

RN 289-06-5 HCPLUS

CN 1,3,4-Thiadiazole (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 9041-92-3 HCPLUS

CN Trypsin inhibitor, .alpha.1- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9041-92-3 HCPLUS

CN Trypsin inhibitor, .alpha.1- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 11120-54-0 HCAPLUS
 CN Oxadiazole (9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 37306-44-8 HCAPLUS
 CN Triazole (6CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 179752-50-2 HCAPLUS
 CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[[5-[3-(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-3-yl]carbonyl]propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 179752-51-3 HCAPLUS
 CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[[5-(2-phenylethyl)-1,2,4-oxadiazol-3-yl]carbonyl]propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179752-52-4 HCAPLUS
 CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[[5-[(2-methoxyphenyl)methyl]-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-53-5 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-54-6 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-(methyl-1,2,4-oxadiazol-3-yl)carbonyl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 179752-55-7 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[(5-

(difluoromethyl)-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 179752-56-8 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-(difluoromethyl)-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-57-9 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[(5-[(3-methoxyphenyl)methyl]-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-58-0 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[(5-[(2,6-difluorophenyl)methyl]-1,2,4-oxadiazol-3-yl)carbonyl]-2-methylpropyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 179752-59-1 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-[(1E)-2-phenylethenyl]-1,2,4-oxadiazol-3-yl)carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.




RN 179752-60-4 HCAPLUS
 CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[[5-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 179752-61-5 HCAPLUS
 CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[[5-[(1E)-2-(4-methoxyphenyl)ethenyl]-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 179752-62-6 HCAPLUS
 CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[[5-(3-thienylmethyl)-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-64-8 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy) carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-phenyl-1,2,4-oxadiazol-3-yl) carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-65-9 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy) carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-(3-phenylpropyl)-1,2,4-oxadiazol-3-yl) carbonyl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 208840-11-3 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy) carbonyl]-L-valyl-N-[(1S)-1-[[5-[(3,5-

dimethylphenyl)methyl]-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-12-4 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[[5-[(3,5-dimethoxyphenyl)methyl]-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-13-5 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[[5-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-14-6 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[[5-[(3-methylphenyl)methyl]-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-18-0 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[[5-[(1,1'-biphenyl)-4-ylmethyl]-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-19-1 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[[5-((1,1'-biphenyl)-3-yl)methyl]-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-20-4 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[[5-((3-phenoxyphenyl)methyl)-1,2,4-oxadiazol-3-yl]carbonyl]propyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-21-5 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[[5-(cyclohexylmethyl)-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-22-6 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl)carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-24-8 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 208840-25-9 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-

[[3-(trifluoromethyl)phenyl]methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-27-1 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[[5-(1-naphthalenylmethyl)-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-28-2 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[[5-(3-pyridinylmethyl)-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-39-5 HCPLUS

CN 1(6H)-Pyrimidineacetamide, 5-amino-2-(4-fluorophenyl)-N-[(1S)-2-methyl-1-[[5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]-6-oxo-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 208845-34-5 HCPLUS

CN Carbamic acid, [2-(4-fluorophenyl)-1,6-dihydro-1-[2-[(1S)-2-methyl-1-[[5-[(3-(trifluoromethyl)phenyl)methyl]-1,2,4-oxadiazol-3-yl]carbonyl]propyl]amino]-2-oxoethyl]-6-oxo-5-pyrimidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-35-6 HCAPLUS

CN 1(6H)-Pyrimidineacetamide, 5-amino-2-(4-fluorophenyl)-N-[(1S)-2-methyl-1-[[5-[[3-(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-3-yl]carbonyl]propyl]-6-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-38-9 HCAPLUS

CN Carbamic acid, [2-(4-fluorophenyl)-1,6-dihydro-1-[2-[(1S)-2-methyl-1-[[5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]amino]-2-oxoethyl]-6-oxo-5-pyrimidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-39-0 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-[(1,1':3',1''-terphenyl)-5'-ylmethyl]-1,2,4-oxadiazol-3-yl)carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-40-3 HCAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-methyl-1-[(5-[(trifluoromethyl)phenyl]methyl)-1,2,4-oxadiazol-3-yl)carbonyl]propyl]amino]-2-oxoethyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-43-6 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[(5-[(dimethylamino)phenyl]methyl)-1,3,4-oxadiazol-2-yl]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-56-1 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[[5-[(4-dimethylamino)phenyl]methyl]-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-62-9 HCAPLUS

CN 3-Thiazolidineacetamide, N-[(1S)-2-methyl-1-[[5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]-4-oxo-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 208845-63-0 HCAPLUS

CN 3-Thiazolidineacetamide, N-[(1S)-2-methyl-1-[[5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]-4-oxo-2-(phenylmethyl)- (9CI) (CA INDEX NAME)

INDEX NAME)


Absolute stereochemistry.



RN 208845-65-2 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy) carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[[5-(1-naphthalenylmethyl)-1,3,4-oxadiazol-2-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-66-3 HCPLUS


CN Carbamic acid, [(1S)-1-[(2S)-2,3-dihydro-2-[[[(1S)-2-methyl-1-[[5-[(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-3-yl]carbonyl]propyl]amino]carbonyl]-1H-indol-1-yl]carbonyl]-2-methylpropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 208845-77-6 HCAPLUS
 CN 3-Thiazolidineacetamide, N-[(1S)-2-methyl-1-[[5-[[3-(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-3-yl]carbonyl]propyl]-4-oxo-2-(phenylmethyl)-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 208845-85-6 HCAPLUS
 CN Carbamic acid, [(1S)-1-[(2S)-2,3-dihydro-2-[[[(1S)-2-methyl-1-[[5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]amino]carbonyl]-1H-indol-1-yl]carbonyl]-2-methylpropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208846-02-0 HCAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[2-[(1S)-2-methyl-1-[[5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]amino]-2-oxoethyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208846-03-1 HCAPLUS
 CN 1H-Indole-2-carboxamide, 1-acetyl-2,3-dihydro-N-[(1S)-2-methyl-1-[[5-[(3-

methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]-, (2S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 208846-13-3 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[(5-(1,3-benzodioxol-5-ylmethyl)-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208847-42-1 HCAPLUS

CN Carbamic acid, [(2S,5S)-1,2,4,5,6,7-hexahydro-2-[[[(1S)-2-methyl-1-[(5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]amino]carbonyl]-4-oxoazepino[3,2,1-hi]indol-5-yl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208847-55-6 HCAPLUS

CN 3-Thiazolidineacetamide, N-[(1*S*)-1-[hydroxy[5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]methyl]-2-methylpropyl]-4-oxo-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 37259-58-8, Serine protease

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(serine protease inhibitors for inhibiting apoptosis, and therapeutic use)

RN 37259-58-8 HCAPLUS

CN Proteinase, serine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L9 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:628008 HCAPLUS

DOCUMENT NUMBER: 133:217724

TITLE: Inhibitors of serine protease

activity, and methods and compositions for treatment of nitric oxide-induced clinical conditions

INVENTOR(S): Shapiro, Leland

PATENT ASSIGNEE(S): The Trustees of University Technology Corp., USA

SOURCE: PCT Int. Appl., 50 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 4


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000051623	A2	20000908	WO 2000-US5556	20000303
WO 2000051623	A3	20001214		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6489308	B1	20021203	US 2000-518097	20000303
PRIORITY APPLN. INFO.:				
US 1999-123167P P 19990305				
US 1999-156523P P 19990929				

AB. A method of treating and preventing diseases is provided. In particular, compns. and methods of blocking diseases assocd. with aberrant levels of nitric oxide and facilitated by a serine proteolytic activity are disclosed, which consist of administering to a subject a therapeutically effective amt. of a compd. having a **serine protease** inhibitory activity. Among effective compds. are .alpha.1-antitrypsin and synthetic drugs mimicking some or all of the actions of .alpha.1-antitrypsin.

IT 289-06-5D, Thiadiazole, derivs. 11120-54-0D, Oxadiazole, derivs. 37306-44-8D, Triazole, peptoid derivs.
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (inhibitors; **serine protease** inhibitors for treatment of NO-induced diseases)

RN 289-06-5 HCAPLUS
 CN 1,3,4-Thiadiazole (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 11120-54-0 HCAPLUS
 CN Oxadiazole (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 37306-44-8 HCAPLUS
 CN Triazole (6CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 9004-06-2, Elastase 128028-50-2, Proteinase-3
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors; **serine protease** inhibitors for

treatment of NO-induced diseases)

RN 9004-06-2 HCPLUS
 CN Elastase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 128028-50-2 HCPLUS
 CN Myeloblastin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 9041-92-3, .alpha.1-Antitrypsin 179752-50-2
 179752-51-3 179752-52-4 179752-53-5
 179752-54-6 179752-55-7 179752-56-8
 179752-57-9 179752-58-0 179752-59-1
 179752-60-4 179752-61-5 179752-62-6
 179752-64-8 179752-65-9 208840-11-3
 208840-12-4 208840-13-5 208840-14-6
 208840-18-0 208840-19-1 208840-20-4
 208840-21-5 208840-22-6 208840-24-8
 208840-25-9 208840-27-1 208840-28-2
 208840-39-5 208845-34-5 208845-35-6
 208845-38-9 208845-39-0 208845-40-3
 208845-43-6 208845-56-1 208845-62-9
 208845-63-0 208845-65-2 208845-66-3
 208845-77-6 208845-85-6 208846-02-0
 208846-03-1 208846-13-3 208847-42-1
 208847-55-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(serine protease inhibitors for treatment of NO-induced diseases)

RN 9041-92-3 HCPLUS
 CN Trypsin inhibitor, .alpha.1- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 179752-50-2 HCPLUS
 CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[[5-[[3-(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-51-3 HCPLUS
 CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[[5-

(2-phenylethyl)-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-52-4 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[[5-[(2-methoxyphenyl)methyl]-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-53-5 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-54-6 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy) carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-methyl-1,2,4-oxadiazol-3-yl) carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-55-7 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy) carbonyl]-L-valyl-N-[(1S)-1-[(5-(difluoromethyl)-1,2,4-oxadiazol-3-yl) carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 179752-56-8 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy) carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[[5-

(phenylmethyl)-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-57-9 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[[5-[(3-methoxyphenyl)methyl]-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-58-0 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[[5-[(2,6-difluorophenyl)methyl]-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 179752-59-1 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-[(1E)-2-phenylethenyl]-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 179752-60-4 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 179752-61-5 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[[5-[(1E)-2-(4-methoxyphenyl)ethenyl]-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 179752-62-6 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[[5-(3-thienylmethyl)-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-64-8 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy) carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-phenyl-1,2,4-oxadiazol-3-yl) carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179752-65-9 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy) carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-(3-phenylpropyl)-1,2,4-oxadiazol-3-yl) carbonyl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 208840-11-3 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy) carbonyl]-L-valyl-N-[(1S)-1-[(5-[(3,5-

dimethylphenyl)methyl]-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-12-4 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[[5-[(3,5-dimethoxyphenyl)methyl]-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-13-5 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[[5-[(3,5-bis(trifluoromethyl)phenyl)methyl]-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-14-6 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-[(3-methylphenyl)methyl]-1,2,4-oxadiazol-3-yl)carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-18-0 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[(5-[(1,1'-biphenyl)-4-ylmethyl]-1,2,4-oxadiazol-3-yl)carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-19-1 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[[5-([1,1'-biphenyl]-3-ylmethyl)-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-20-4 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[[5-[(3-phenoxyphenyl)methyl]-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-21-5 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[[5-(cyclohexylmethyl)-1,2,4-oxadiazol-3-yl]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-22-6 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl)carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-24-8 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 208840-25-9 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-

[[3-(trifluoromethyl)phenyl]methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-27-1 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[[5-(1-naphthalenylmethyl)-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-28-2 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[[5-(3-pyridinylmethyl)-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208840-39-5 HCPLUS

CN 1(6H)-Pyrimidineacetamide, 5-amino-2-(4-fluorophenyl)-N-[(1S)-2-methyl-1-[[5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]-6-oxo-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 208845-34-5 HCPLUS

CN Carbamic acid, [2-(4-fluorophenyl)-1,6-dihydro-1-[2-[(1S)-2-methyl-1-[[5-[(3-(trifluoromethyl)phenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]amino]-2-oxoethyl]-6-oxo-5-pyrimidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-35-6 HCAPLUS

CN 1(6H)-Pyrimidineacetamide, 5-amino-2-(4-fluorophenyl)-N-[(1S)-2-methyl-1-[[5-[[3-(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-3-yl]carbonyl]propyl]-6-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-38-9 HCAPLUS

CN Carbamic acid, [2-(4-fluorophenyl)-1,6-dihydro-1-[2-[(1S)-2-methyl-1-[[5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]amino]-2-oxoethyl]-6-oxo-5-pyrimidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-39-0 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-([1,1':3',1''-terphenyl]-5'-ylmethyl)-1,2,4-oxadiazol-3-yl]carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-40-3 HCAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[2-[(1S)-2-methyl-1-[(5-[(trifluoromethyl)phenyl]methyl)-1,2,4-oxadiazol-3-yl]carbonyl]propyl]amino]-2-oxoethyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-43-6 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[(5-[(dimethylamino)phenyl]methyl)-1,3,4-oxadiazol-2-yl]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-56-1 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[(5-[(4-(dimethylamino)phenyl)methyl]-1,2,4-oxadiazol-3-yl)carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-62-9 HCAPLUS

CN 3-Thiazolidineacetamide, N-[(1S)-2-methyl-1-[(5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl)carbonyl]propyl]-4-oxo-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 208845-63-0 HCAPLUS

CN 3-Thiazolidineacetamide, N-[(1S)-2-methyl-1-[(5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl)carbonyl]propyl]-4-oxo-2-(phenylmethyl)- (9CI) (CA INDEX NAME)

(INDEX NAME)


Absolute stereochemistry.



RN 208845-65-2 HCPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-2-methyl-1-[(5-(1-naphthalenylmethyl)-1,3,4-oxadiazol-2-yl)carbonyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-66-3 HCPLUS

CN Carbamic acid, [(1S)-1-[(2S)-2,3-dihydro-2-[[[(1S)-2-methyl-1-[(5-(trifluoromethyl)phenyl)methyl]-1,2,4-oxadiazol-3-yl)carbonyl]propyl]amino]carbonyl]-1H-indol-1-yl]carbonyl]-2-methylpropyl-phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-77-6 HCAPLUS

CN 3-Thiazolidineacetamide, N-[(1S)-2-methyl-1-[[5-[[3-(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-3-yl]carbonyl]propyl]-4-oxo-2-(phenylmethyl)-, 1-oxide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208845-85-6 HCAPLUS

CN Carbamic acid, [(1S)-1-[[[(2S)-2,3-dihydro-2-[[[(1S)-2-methyl-1-[[5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]amino]carbonyl]-1H-indol-1-yl]carbonyl]-2-methylpropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208846-02-0 HCAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[2-[(1S)-2-methyl-1-[[5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]amino]-2-oxoethyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 208846-03-1 HCAPLUS

CN 1H-Indole-2-carboxamide, 1-acetyl-2,3-dihydro-N-[(1S)-2-methyl-1-[(5-[(3-

methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]-, (2S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 208846-13-3 HCAPLUS

CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-[(5-(1,3-benzodioxol-5-ylmethyl)-1,2,4-oxadiazol-3-yl)carbonyl]-2-methylpropyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208847-42-1 HCAPLUS

CN Carbamic acid, [(2S,5S)-1,2,4,5,6,7-hexahydro-2-[[[(1S)-2-methyl-1-[[5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]amino]carbonyl]-4-oxoazepino[3,2,1-hi]indol-5-yl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208847-55-6 HCPLUS

CN 3-Thiazolidineacetamide, N-[(1S)-1-[hydroxy[5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]methyl]-2-methylpropyl]-4-oxo-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

